Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma

Tumor hypoxia is a major cause of treatment failure for a variety of malignancies. However, hypoxia also leads to treatment opportunities as demonstrated by the development of compounds that target regions of hypoxia within tumors. Evofosfamide is a hypoxia‐activated prodrug that is created by linki...

Descripción completa

Detalles Bibliográficos
Autores principales: Liapis, Vasilios, Zysk, Aneta, DeNichilo, Mark, Zinonos, Irene, Hay, Shelley, Panagopoulos, Vasilios, Shoubridge, Alexandra, Difelice, Christopher, Ponomarev, Vladimir, Ingman, Wendy, Atkins, Gerald J., Findlay, David M., Zannettino, Andrew C. W., Evdokiou, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Cancer Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603834/
https://www.ncbi.nlm.nih.gov/pubmed/28799237
http://dx.doi.org/10.1002/cam4.1115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603834/
https://www.ncbi.nlm.nih.gov/pubmed/28799237
http://dx.doi.org/10.1002/cam4.1115

Ejemplares similares